{
    "id": 32572,
    "fullName": "PPM1D mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PPM1D mutant indicates an unspecified mutation in the PPM1D gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 8493,
        "geneSymbol": "PPM1D",
        "terms": [
            "PPM1D",
            "IDDGIP",
            "JDVS",
            "PP2C-DELTA",
            "WIP1"
        ]
    },
    "variant": "mutant",
    "createDate": "02/11/2020",
    "updateDate": "02/11/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20806,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 treatment reduced viability and enhanced apoptosis in an acute myeloid leukemia cell line expressing PPM1D frameshift mutations in culture (PMID: 29954749).",
            "molecularProfile": {
                "id": 35118,
                "profileName": "PPM1D mutant"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18050,
                    "pubMedId": 29954749,
                    "title": "PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954749"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20807,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 and Cytosar-U (cytarabine) treatment demonstrated increased sensitivity and reduced viability of an acute myeloid leukemia cell line expressing PPM1D frameshift mutations in culture (PMID: 29954749).",
            "molecularProfile": {
                "id": 35118,
                "profileName": "PPM1D mutant"
            },
            "therapy": {
                "id": 9456,
                "therapyName": "Cytarabine + GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18050,
                    "pubMedId": 29954749,
                    "title": "PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954749"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35118,
            "profileName": "PPM1D mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}